治部,连载,面向日本版NIH建立新指标体系——之一 基于新指标体系的制药产业现状俯瞰与未来预测

Development of new indicators for the launch of a Japanese version of the NIH An Overview and Future Prospects of Pharmaceutical Industry Based on New Indicators

日本版NIH及其制药企业,政策制定·战略规划需要佐证。为此,本研究尝试基于新的指标体系进行制药产业的现状俯瞰与未来预测。连载第一篇,着眼于制药产业研究开发的pipeline,即在研药物。按照研究开发阶段来梳理pipeline,通过与已上市药物数量的比较,显然可以把握各国目前及未来的研发能力。该结果凸现出了美国在研发中的优势,以及日本的特异性等。

For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried an overview and future prospects of pharmaceutical industry based on new indicators. We focused on the R＆D pipelines of each pharmaceutical company. The results show that the R＆D capacity of each country in the current stage and in future can be measured, by structuring the pipeline data in each R＆D step, comparing the number of marketed pharmaceuticals and so on Consequently, the competitive advantage of US and the idiosyncrasy of Japan have been thrown into sharp relief.